Cargando…
Performance of a universal prenatal screening program incorporating cell-free fetal DNA analysis in Ontario, Canada
BACKGROUND: The emergence of cell-free fetal DNA (cfDNA) testing technology has disrupted the landscape of prenatal screening for trisomies 21 (T21) and 18 (T18). Publicly funded systems around the world are grappling with how to best integrate this more accurate but costly technology, as there is l...
Autores principales: | Dougan, Shelley D., Okun, Nan, Bellai-Dussault, Kara, Meng, Lynn, Howley, Heather E., Huang, Tianhua, Reszel, Jessica, Lanes, Andrea, Walker, Mark C., Armour, Christine M. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
CMA Joule Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8354647/ https://www.ncbi.nlm.nih.gov/pubmed/34344770 http://dx.doi.org/10.1503/cmaj.202456 |
Ejemplares similares
-
Correction to “Performance of a universal prenatal screening program incorporating cell-free fetal DNA analysis in Ontario, Canada”
Publicado: (2021) -
Maternal-Newborn Health System Changes and Outcomes in Ontario, Canada, During Wave 1 of the COVID-19 Pandemic—A Retrospective Study
por: Roberts, Nicole F., et al.
Publicado: (2022) -
Data Quality Assessment on Congenital Anomalies in Ontario, Canada
por: Miao, Qun, et al.
Publicado: (2020) -
Practice guideline: joint CCMG-SOGC recommendations for the use of chromosomal microarray analysis for prenatal diagnosis and assessment of fetal loss in Canada
por: Armour, Christine M, et al.
Publicado: (2018) -
Perinatal and pediatric outcomes associated with the use of fertility treatment: a population-based retrospective cohort study in Ontario, Canada
por: Dimanlig-Cruz, Sheryll, et al.
Publicado: (2023)